BSc (Biological Sciences), 1995
SFU OUTSTANDING ALUMNI RECIPIENT, 2007
Dr. David Granville graduated from SFU (B.Sc., Biological Sciences) in 1995. He was also involved in the SFU Co-op Education program, providing an introduction to biotechnology and ultimately inspiring him to pursue biomedical research as a career. In 1995, he was hired by QLT, Inc. While at QLT, he completed his Ph.D. and was promoted to Scientist. His R&D studies at QLT (1994-2001) supported the approval of Visudyne® as the first treatment for macular degeneration, the leading cause of blindness in the elderly. In 1999 Visudyne® was approved by the FDA resulting in the largest ophthalmic product release in history. Dr. Granville’s research is cited on the drug label for Visudyne®. In 2001, Dr. Granville relocated to the Scripps Research Institute (San Diego, CA) where he discovered a novel therapeutic target for cardiovascular disease that led to the formation of Radical Therapeutix. Dr. Granville has received numerous awards including a Canada Research Chair, Canada Top 40 Under 40™ Award, Business in Vancouver Top Forty Under 40, Canadian Association of Pathology Junior Scientist Award, 2006 UBC Outstanding Young Alumnus Award, the 2007 SFU Outstanding Alumni Award for Academic Achievement, and was a runner-up for the American Heart Association Katz Basic Science Prize. His research is now focused on conditions associated with aging and chronic inflammation. Discoveries arising from this work have led to the incorporation of viDA Therapeutics; Dr. Granville is a Founder and Chief Scientific Officer of viDA. Dr. Granville is presently a Professor in the Department of Pathology and Laboratory Medicine at UBC, Director of the GEM Facility at the Centre for Heart Lung Innovation at St. Paul’s Hospital, and an Adjunct Professor in the dept of Molecular Biology & Biochemistry at SFU.
To read more about David, please visit: